Publications by authors named "Kurt Marhardt"

Claim this Profile
F
Family planning and contraception in people with multiple sclerosis: perspectives for obstetricians, gynaecologists, and other health care professionals involved in reproductive planning.
Gabriele S Merki-Feld, Riley Bove, Lisa B Haddad, Kerstin Hellwig, Jan Hillert, Kurt Marhardt

Eur J Contracept Reprod Health Care· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the duration of EDSS improvement after a therapy start: A novel approach applied to the long-term extension of the PRISMS study.
Alessio Signori, Francesca Bovis, Irene Schiavetti, Marta Ponzano, Mark S Freedman, Kurt Marhardt

Mult Scler Relat Disord· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database.
Arthur Allignol, Emmanuelle Boutmy, Meritxell Sabidó Espin, Kurt Marhardt, Patrick Vermersch

Front Neurol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a.
Maria Pia Sormani, Mark S Freedman, Julie Aldridge, Kurt Marhardt, Ludwig Kappos

Mult Scler Relat Disord· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a.
Mark S Freedman, Giancarlo Comi, Patricia K Coyle, Julie Aldridge, Liang Chen, Kurt Marhardt

Mult Scler Relat Disord· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of daily high-dose vitamin D in patients with RRMS receiving subcutaneous interferon β-1a.
Raymond Hupperts, Joost Smolders, Reinhold Vieth, Trygve Holmøy, Kurt Marhardt

Neurology· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
Giancarlo Comi, Nicola De Stefano, Mark S Freedman, Frederik Barkhof, Bernard M J Uitdehaag, Kurt Marhardt

J Neurol Neurosurg Psychiatry· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Antonios Bayas, Jean Christophe Ouallet, Boris Kallmann, Raymond Hupperts, Ulrich Fulda, Kurt Marhardt

Expert Opin Drug Deliv· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
Raymond Hupperts, Lizette Ghazi-Visser, Ana Martins Silva, Michalis Arvanitis, Hanna Kuusisto, Kurt Marhardt

Clin Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis